Weekly Paclitaxel, Carboplatin, and Cetuximab (PCC) as Treatment for Recurrent or Metastatic Head and Neck Squamous-cell Carcinoma (RM-HNSCC) that Progressed on Immune Checkpoint Inhibitors (ICI): A Retrospective Analysis

We report the outcomes of pts treated with weekly PCC after progression on ICI.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: M. Bonomi, H. Abu-Sbeih, B. Klamer, M. Issa, F. Rind, K. Dibs, D.J. Konieczkowski, E. Gogineni, J. Pan, M. Old, E. Tili, A. Chakravarti, J.C. Grecula, S. Baliga, R. Carrau, J.W. Rocco, D.M. Blakaj, P. Bhateja Tags: 159 Source Type: research